Mesial temporal sclerosis (MTS) cannot be cured in the sense of reversing the brain damage that has already occurred. The scarring and shrinkage of the hippocampus are permanent structural changes. However, the seizures caused by MTS can often be eliminated or dramatically reduced, primarily through surgery. For most people searching this question, that distinction matters: you may not be able to undo the scarring, but you can frequently stop it from ruining your life.
What Happens in the Brain
MTS involves the loss of neurons in the hippocampus, a structure deep in the temporal lobe that plays a central role in forming new memories. As cells die, the hippocampus shrinks and develops scar tissue. On an MRI, this shows up as a smaller hippocampus with abnormally bright signal on certain sequences. The scarred tissue becomes electrically unstable and generates seizures, which is why MTS is the most common structural finding in people with drug-resistant temporal lobe epilepsy.
The damage tends to be progressive. Longer epilepsy duration correlates with greater hippocampal volume loss, and the repeated seizures themselves may worsen the scarring over time. The abnormal electrical activity can also degrade white matter pathways connecting the hippocampus to other brain regions, meaning the effects aren’t confined to one spot. This is one reason early intervention matters: the longer seizures go uncontrolled, the more widespread the damage becomes.
Why Medication Usually Isn’t Enough
Anti-seizure medications are always the first treatment, but MTS is notoriously resistant to them. Among patients with drug-resistant temporal lobe epilepsy and hippocampal sclerosis, fewer than 5% who continue on medications alone enter remission each year. By contrast, roughly 70% of those who undergo surgical resection achieve seizure freedom. In one randomized trial, 73% of surgically treated patients were seizure-free at two years, while none of the patients assigned to medication-only treatment reached that outcome.
The International League Against Epilepsy recommends referring any patient with drug-resistant epilepsy for surgical evaluation after just two failed medications. Despite this, many people spend years or even decades cycling through drugs before being considered for surgery.
Surgical Resection: The Strongest Option
Anterior temporal lobectomy (ATL) is the most established surgical treatment for MTS. The procedure removes the scarred portion of the hippocampus along with surrounding temporal lobe tissue. Across studies, 58 to 73% of MTS patients achieve complete seizure freedom (classified as Engel Class I), and another 21% experience significant improvement. These rates are higher than for most other types of epilepsy surgery, partly because MTS provides a clearly identifiable target.
Long-term outcomes are encouraging but not perfect. Among patients who are seizure-free in the first year after surgery, about 72% remain seizure-free at five years and 56% at ten years. That means some people do experience seizure recurrence over time. The good news is that among those who relapse, about half have no more than one seizure per year, a dramatic improvement over their pre-surgical baseline.
Memory and Cognitive Risks
Because the hippocampus is essential for memory, removing it carries cognitive trade-offs. The risk is greatest when surgery is performed on the language-dominant side of the brain (typically the left hemisphere). Patients undergoing left-sided surgery commonly experience measurable declines in verbal memory and word-finding ability, and these deficits can worsen over the first two years. Right-sided surgery carries less verbal memory risk, with initial declines often returning to baseline within two years. These cognitive effects are a real consideration, and surgical teams weigh them carefully against the benefits of seizure control.
Laser Ablation: A Less Invasive Alternative
MRI-guided laser interstitial thermal therapy (known as laser ablation) offers a minimally invasive alternative to open surgery. Instead of removing tissue, a thin laser fiber is threaded through a small hole in the skull and used to heat and destroy the scarred hippocampal tissue. Recovery is faster, and the procedure typically requires only one or two nights in the hospital compared to several days for open surgery.
The trade-off is a lower seizure freedom rate. A meta-analysis comparing the two approaches found that 72.5% of patients achieved seizure freedom after open resection, compared to 57.1% after laser ablation. Complication rates were lower with laser ablation, particularly for minor, transient complications (4.1% versus 9.9%). Major complication rates were similar between the two approaches, around 2 to 3%. Laser ablation is often considered for patients who want a less invasive option or who have higher surgical risk factors.
Neurostimulation for Non-Surgical Candidates
Not everyone with MTS is a candidate for resection or ablation. Some people have seizures originating from both temporal lobes, or the scarring sits too close to critical brain structures. For these patients, implanted neurostimulation devices offer another path. Two main options exist: responsive neurostimulation (RNS), which detects abnormal electrical activity and delivers targeted pulses to interrupt it, and deep brain stimulation (DBS), which sends continuous or scheduled electrical signals to specific brain targets.
Neither device typically eliminates seizures entirely, but the reductions can be substantial. In a meta-analysis, DBS targeting the hippocampus directly reduced seizures by 70% on average, while RNS reduced them by about 63.5%. Notably, DBS of the hippocampus performed significantly better in patients with MTS compared to those with normal-appearing brain imaging, suggesting the well-defined structural abnormality in MTS gives the stimulator a clearer target.
What Uncontrolled Seizures Cost Over Time
The risks of leaving MTS-related seizures untreated extend well beyond the seizures themselves. Refractory epilepsy carries increased mortality risk from several causes, including sudden unexpected death in epilepsy (SUDEP), accidents during seizures, and higher rates of depression and suicide. There are also cumulative physical consequences: bone density loss from long-term medication use, injury from falls, and progressive brain changes from repeated seizures. The social toll includes driving restrictions, employment difficulties, and stigma. These compounding risks are part of why epilepsy specialists push for early surgical evaluation rather than indefinite medication trials.
The Realistic Outlook
If “cure” means restoring the hippocampus to its original state, MTS cannot be cured. The neurons that have died and the scar tissue that replaced them are irreversible changes. But if “cure” means living without seizures, that outcome is achievable for the majority of people who pursue surgery. Roughly 60 to 73% of surgical patients reach complete seizure freedom, and many others see life-changing reductions. The key variable is timing. People who are evaluated early, after failing just two medications, tend to have better outcomes than those who wait years or decades while the damage progresses and the epileptic network expands.